Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Aug;44(8):1762-1767.
doi: 10.1111/liv.15939. Epub 2024 Apr 10.

Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence

Stefano Ciardullo  1   2 , Alessandro Mantovani  3 , Mario Luca Morieri  4 , Emanuele Muraca  1 , Pietro Invernizzi  5   6 , Gianluca Perseghin  1   2
Affiliations
Meta-Analysis

Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence

Stefano Ciardullo et al. Liver Int. 2024 Aug.

Abstract

A recent Delphi consensus proposed a new definition for metabolic dysfunction associated steatotic liver disease (MASLD) and introduced a disease entity called MetALD, a condition in which steatotic liver disease (SLD), metabolic dysfunction and moderate alcohol intake coexist. Given the limited available data on the prognostic implications of these disease entities, we performed a systematic review and meta-analysis of available cohort studies to evaluate the association of MASLD and MetALD with hard clinical outcomes. We included 5 studies for a total of 9 824 047 participants. Compared with participants without SLD, increased rates of all-cause mortality and incident cardiovascular disease were present for both MASLD and MetALD. Moreover, MetALD was also associated with significantly higher risks of cancer-related mortality (n = 2 studies, random-effects HR 2.10, 95% CI 1.35-3.28) and cardiovascular mortality (n = 3 studies, random-effects HR 1.17, 95% CI 1.12-1.22). Although preliminary, available evidence indicates a more unfavourable prognosis for patients with MetALD compared with those with MASLD.

Keywords: MASLD; MetALD; cardiovascular disease; mortality.

PubMed Disclaimer

References

REFERENCES

    1. Younossi ZM, Alqahtani SA, Alswat K, et al. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024;80(3):419‐430.
    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multi‐society Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29(1):101133.
    1. Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2023;80:e76‐e77.
    1. Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;43:2425‐2433.
    1. Israelsen M, Torp N, Johansen S, Thiele M, Krag A. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease. Lancet Gastroenterol Hepatol. 2023;8(10):866‐868.

LinkOut - more resources